Richmond, VA, United States of America

Richard A Glennon


Average Co-Inventor Count = 1.4

ph-index = 5

Forward Citations = 258(Granted Patents)


Location History:

  • Midlothian, VA (US) (2002 - 2003)
  • Richmond, VA (US) (1996 - 2004)

Company Filing History:


Years Active: 1996-2004

Loading Chart...
13 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Richard A. Glennon

Introduction

Richard A. Glennon is a prominent inventor based in Richmond, VA, known for his significant contributions to the field of pharmacology. With a total of 13 patents to his name, Glennon has made remarkable strides in the development of therapeutic agents aimed at treating mental disorders. His work has had a profound impact on the understanding and treatment of conditions such as depression and anxiety.

Latest Patents

Among his latest patents, Glennon has developed selective serotonin receptor antagonists, specifically focusing on compounds such as Spiro[9,10-dihydroanthracene]-9,3'-pyrrolidine (SPAN) and its derivatives. These compounds serve as selective, high-affinity antagonists of 5-HT serotonin receptors, proving useful as antidepressant and antianxiety agents. Additionally, he has identified selective 5-HT6 receptor ligands that exhibit enhanced affinity and selectivity for 5-HT receptors. These compounds hold therapeutic potential for treating mental disorders and can be utilized in screening methodologies to identify further antagonists of 5-HT receptors.

Career Highlights

Glennon's career has been marked by his association with esteemed institutions such as Virginia Commonwealth University and Cambridge Neuroscience, Inc. His work in these organizations has facilitated groundbreaking research and development in the field of neuroscience and pharmacology.

Collaborations

Throughout his career, Glennon has collaborated with notable individuals in the field, including Bryan Roth and Ho Law. These partnerships have contributed to the advancement of research and innovation in mental health treatments.

Conclusion

Richard A. Glennon's innovative work in the development of serotonin receptor antagonists has significantly advanced the field of mental health treatment. His contributions continue to influence the therapeutic landscape, providing hope for those affected by mental disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…